Primary: To assess the dose response and efficacy of three different dose levels of Auxora in Patients with AP and accompanying SIRS; To assess the time to medically indicated discharge in patients who are responders to early tolerance of solid food intake versus non-responders. Secondary: To assess the safety and tolerability of varying doses of Auxora in patients with AP and accompanying SIRS.
What is the full name of this clinical trial?
A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of Auxora in Patients with Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome